The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.